133 related articles for article (PubMed ID: 8827856)
1. Age of illness onset and schizophrenic symptomatology during an inpatient washout period.
Sharma RP; Dowd SM; Davis JM; Janicak PG
Schizophr Res; 1996 Jul; 20(3):295-300. PubMed ID: 8827856
[TBL] [Abstract][Full Text] [Related]
2. Effect size of symptom status in withdrawal of typical antipsychotics and subsequent clozapine treatment in patients with treatment-resistant schizophrenia.
Pickar D; Bartko JJ
Am J Psychiatry; 2003 Jun; 160(6):1133-8. PubMed ID: 12777272
[TBL] [Abstract][Full Text] [Related]
3. Untreated psychosis and long-term outcome in schizophrenia.
Waddington JL; Scully PJ
Schizophr Bull; 1998; 24(1):34-5. PubMed ID: 9502545
[No Abstract] [Full Text] [Related]
4. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
[TBL] [Abstract][Full Text] [Related]
5. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness.
Haas GL; Garratt LS; Sweeney JA
J Psychiatr Res; 1998; 32(3-4):151-9. PubMed ID: 9793868
[TBL] [Abstract][Full Text] [Related]
6. [Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].
Wolf MA; Bailly L; Diener JM; Martinet JP; Peretti S; Garneau Y
Encephale; 1991; 17(4):255-61. PubMed ID: 1683626
[TBL] [Abstract][Full Text] [Related]
7. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
8. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
[TBL] [Abstract][Full Text] [Related]
9. Placebo washout in trials of antipsychotic drugs.
Volavka J; Cooper TB; Laska EM; Meisner M
Schizophr Bull; 1996; 22(4):567-76. PubMed ID: 8938911
[TBL] [Abstract][Full Text] [Related]
10. Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings.
Finkelstein JR; Cannon TD; Gur RE; Gur RC; Moberg P
J Abnorm Psychol; 1997 May; 106(2):203-12. PubMed ID: 9131840
[TBL] [Abstract][Full Text] [Related]
11. Clinical predictors of relapse following neuroleptic withdrawal.
Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
[TBL] [Abstract][Full Text] [Related]
12. Symptomatic response to antipsychotics differs between recent onset and recurrent chronic schizophrenic patients.
Hill C; Keks NA; Jackson H; Kulkarni J; Hannah D; Copolov D; Singh B
Aust N Z J Psychiatry; 1992 Sep; 26(3):417-22. PubMed ID: 1358053
[TBL] [Abstract][Full Text] [Related]
13. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
Loas G; Noisette C; Legrand A; Delahousse J
Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
[TBL] [Abstract][Full Text] [Related]
14. RBC and plasma choline in neuroleptic-treated schizophrenic patients.
Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ
Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429
[TBL] [Abstract][Full Text] [Related]
15. Zotepine in the treatment of acute hospitalized schizophrenic episodes.
Kasper S; Quiner S; Barnas C; Fabisch H; Haushofer M; Sackel C; König P; Lingg A; Platz T; Rittmannsberger H; Stuppäck C; Willeit M; Zapotoczky HG
Int Clin Psychopharmacol; 2001 May; 16(3):163-8. PubMed ID: 11354238
[TBL] [Abstract][Full Text] [Related]
16. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.
Allan ER; Alpert M; Sison CE; Citrome L; Laury G; Berman I
J Clin Psychiatry; 1996 Oct; 57(10):455-9. PubMed ID: 8909331
[TBL] [Abstract][Full Text] [Related]
18. Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial.
Albert N; Randers L; Allott K; Jensen HD; Melau M; Hjorthøj C; Nordentoft M
Psychol Med; 2019 May; 49(7):1138-1147. PubMed ID: 30058511
[TBL] [Abstract][Full Text] [Related]
19. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
[TBL] [Abstract][Full Text] [Related]
20. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients; relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment.
Wieselgren IM; Lindstrom LH
Acta Psychiatr Scand; 1996 Jan; 93(1):9-19. PubMed ID: 8919324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
